MG
ALGS icon

Michael Gelband’s Aligos Therapeutics ALGS Stock Holding History

Michael Gelband’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-468
Closed -$25K – 1899
2022
Q1 		$25K Buy
+468
New +$37.5K ﹤0.01% 2098

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Michael Gelband's ALGS Position: Q2 2022 in Review

Michael Gelband sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 468 shares — an estimated $25K sold.

Michael Gelband first reported a position in ALGS in Q1 2022 and held it in 1 quarter. The position peaked at $25K in Q1 2022. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

  • Michael Gelband reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Michael Gelband sold 468 Aligos Therapeutics shares in Q2 2022, an estimated $25K.
  • Michael Gelband first reported a position in Aligos Therapeutics in Q1 2022 and held it in 1 quarter.
  • Michael Gelband's Aligos Therapeutics position peaked at $25K in Q1 2022.
  • 59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.